Dr. Christina Rahm and DRC Ventures Accept Prestigious Gold Stevie(R) Award for Patent-Driven Manufacturing Innovation
New York, New York--(Newsfile Corp. - June 24, 2026) - Dr. Christina Rahm, founder and CEO of DRC Ventures, was honored with a Gold Stevie® Award at the 2026 American Business Awards® ceremony in New York City for her groundbreaking work in developing the patent-driven manufacturing infrastructure
Biotechnology, Food / Beverages, Health
2026-06-24 1:20 PM EDT | DRC Ventures
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO Int
Technology, Biotechnology, Healthcare and Hospitals
2026-06-23 8:30 AM EDT | BioMark Diagnostics, Inc.
Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume
Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous ship
Technology, Biotechnology, Health
2026-06-23 6:30 AM EDT | Therma Bright Inc.
Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)
Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers,
Biotechnology, Pharmaceuticals
2026-06-22 7:51 AM EDT | Yellowbird Diagnostics
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operatio
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-22 7:00 AM EDT | Cannabis Bioscience International Holdings
MustGrow Closes $3.7 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its previously announced non-brokered private placement of 7,481,541 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of approximately $3,741,000 (the "LIFE Offering"). Each Unit consists of (i) one common share of the Company (each
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-06-19 5:00 PM EDT | MustGrow Biologics Corp.
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators ("CSA"), the pilot program under
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-06-19 12:16 PM EDT | Neural Therapeutics Inc.
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum
Biotechnology, Healthcare and Hospitals
2026-06-18 8:30 AM EDT | Envoy Medical, Inc.
BioHarvest Sciences to Present at the 2026 BIO International Convention
British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details:
Biotechnology, Pharmaceuticals, Health
2026-06-18 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-18 7:00 AM EDT | Phio Pharmaceuticals Corp.
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. "These data reinforce
Biotechnology, Pharmaceuticals
2026-06-18 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing to begin harnessing predictive AI to further its e-commerce consumer and wholesale sales platform. The initiative is engineered to leverage readily available predictive consumer behavior models to optimize, monetize, and scale the brand'
Technology, Biotechnology, Health
2026-06-18 6:00 AM EDT | Restart Life Sciences Corp.
MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTC: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce that, in connection with its previously announced non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit, and as a res
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-06-17 7:21 PM EDT | MustGrow Biologics Corp.
Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $
Biotechnology, Pharmaceuticals, Health
2026-06-17 5:22 PM EDT | Hemostemix Inc.
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, an
Biotechnology, Pharmaceuticals, Health
2026-06-17 3:15 AM EDT | Defence Therapeutics Inc.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Houston, Texas--(Newsfile Corp. - June 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading under the ticker symbol CBIH, today announced a new chapter in its PTSD-focused research journey, marked by the completion of its patent-related work and the continued exploration of the scientific relationship between cannabinoids and psilocybin in relation to trauma, memory, emotional regulation, and recovery. PTSD affects veterans, first responde
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-15 7:00 AM EDT | Cannabis Bioscience International Holdings
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units
Biotechnology, Pharmaceuticals, Health
2026-06-12 5:39 PM EDT | PreveCeutical Medical Inc.
Bachem Holding AG Announces Capital Markets Day 2026
Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, as well as virtually. This hybrid event will provide insights into the company's strategic priorities, business outlook, and key developments.
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-06-12 11:47 AM EDT | Bachem Holding AG